The primary objectives of this study are in newly diagnosed APL patients:~To evaluate the efficacy (complete and molecular response rates) and toxicity of NRX 195183 in induction therapy~To evaluate the efficacy (molecular response rates) and toxicity of NRX 195183 in combination with arsenic trioxide (As2O3) in consolidation therapy.~To evaluate the efficacy (event free-survival, disease-free survival) and toxicity of NRX 195183 as maintenance therapy for patients with APL who achieve a molecular complete response.
The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.